Format

Send to

Choose Destination
Pain Manag. 2015;5(6):413-23. doi: 10.2217/PMT.15.35. Epub 2015 Aug 3.

A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy.

Author information

1
BioElectronics Corporation, 4539 Metropolitan Ct, Frederick, Maryland, MD 21704, USA.

Abstract

BACKGROUND:

The ActiPatch(®) (BioElectronics Corporation, MD, USA) pulsed shortwave therapy device has been shown to be clinically effective in three double-blind randomized controlled pain studies. However, the effectiveness of this device in a broader population of chronic musculoskeletal pain sufferers, affected by a variety of etiologies in different regions of the body, has not been studied.

AIM:

The objective of this registry study was to assess the effectiveness and satisfaction of the ActiPatch device in the general population of chronic pain sufferers.

METHODS:

A total of 44,000 subjects completed the trial, with 5000 assessments of the device collected.

CONCLUSION:

The ActiPatch device appears to provide a clinically meaningful reduction of chronic musculoskeletal pain affecting different locations of the body caused by a variety of etiologies.

KEYWORDS:

chronic pain; noninvasive; over-the-counter; pulsed shortwave therapy; therapy

PMID:
26235410
DOI:
10.2217/PMT.15.35
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center